The U.S. Food and Drug Administration (FDA) has launched a pilot initiative to expedite the approval process for generic drugs manufactured domestically with active pharmaceutical ingredients sourced within the United States. This abbreviated new drug application (ANDA) pilot aims to reinforce domestic supply chains and reduce reliance on foreign ingredients as part of the Trump administration’s strategy to reshore pharmaceutical production. The program intends to encourage manufacturers to relocate or increase production capacity in the U.S., promising faster review timelines and regulatory support to facilitate this transition.